Compare · BDX vs MMED
BDX vs MMED
Side-by-side comparison of Becton Dickinson and Company (BDX) and MiniMed Group Inc. (MMED): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and MMED operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $48.05B, about 7.6x MMED ($6.31B).
- Over the past year, BDX is down 7.4% and MMED is up 22.9% - MMED leads by 30.3 points.
- MMED has been more active in the news (7 items in the past 4 weeks vs 6 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 13 for MMED).
- Company
- Becton Dickinson and Company
- MiniMed Group Inc.
- Price
- $176.39-1.91%
- $22.43-1.43%
- Market cap
- $48.05B
- $6.31B
- 1M return
- -2.75%
- +13.59%
- 1Y return
- -7.40%
- +22.86%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 6
- 7
- Recent ratings
- 25
- 13
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- EVP & Chief Financial Officer Roque Vitor covered exercise/tax liability with 190 shares, decreasing direct ownership by 2% to 8,041 units (SEC Form 4) (withholding tax)
- EVP, Chief Revenue Officer Feld Michael sold $31,101 worth of shares (165 units at $188.49) as part of a pre-agreed trading plan, decreasing direct ownership by 0.83% to 19,720 units (SEC Form 4)
- BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
- BD to Present at Wells Fargo 21st Annual Healthcare Conference
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
Latest MMED
- SEC Form 10-Q filed by MiniMed Group Inc.
- MiniMed Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
- MiniMed to Participate in Upcoming Investor Conferences
- SEC Form DEFA14A filed by MiniMed Group Inc.
- SEC Form DEF 14A filed by MiniMed Group Inc.
- MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor
- MiniMed Group Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SVP, Gen. Counsel, Corp. Sec. Wills Courtney Nelson covered exercise/tax liability with 1,762 shares, decreasing direct ownership by 1% to 136,384 units (SEC Form 4) (withholding tax)
- EVP Ch. Prod. & Tech Officer Dianaty Ali covered exercise/tax liability with 8,012 shares, decreasing direct ownership by 2% to 315,158 units (SEC Form 4) (withholding tax)